What We Do

AUTO-IMMUNE  and IMMUNE MEDIATED DISEASES

are conditions that results from an abnormal immune system response. In these diseases, the immune system mistakenly targets the body. This creates an inflammatory response that causes damage. 50 million Americans, 20% of the population, have Autoimmune disease, which is one of the top 10 leading causes of death in female children and women in all age groups up to 64 years of age.

Understanding how to modulate immune system activity will benefit among others, transplant recipients, and cancer, AIDS, type-1 diabetes and infectious disease patients. Symptoms cross many specialties and can affect all body organs.

INFECTIOUS DISEASES

are illnesses caused by germs (such as bacteria, viruses, and fungi) that enter the body, multiply, and can cause an infection. Some infectious diseases are contagious (or communicable), meaning they are capable of spreading from one person to another.

CENTRAL NERVOUS SYSTEM  (CNS) DIESEASE

is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function.

PPL's "PPL-X1"

PPL-X1 is an experimental Immune Complex Inhibitor (ICI)

created using Peptide stabilization technology.

PPL-X1 is an experimental 16-mer amino acid semi-cyclic Peptide

with demonstrated capabilities for treating:

· Autoimmune diseases

· Immune-mediated diseases

· Inflammatory diseases

· Infectious diseases (including Covid, Dengue and Zika)

and

· Diseases of the central nervous system (“CNS”).

Further clinical studies could also lead to indications that PPL-X1 ICI can abate the acute and chronic rejection that occurs in tissue and organ transplant patients.

PPL is an early stage next-generation biopharmaceutical company whose science holds the promise to challenge the highly toxic, less effective, expensive, invasive legacy drugs of the last century.

PPL’s lead therapeutic, Phoenix Peptide eXperimental (PPL-X1), is a 1,740 Dalton, 16-mer amino acid peptide optimized for solubility, stability and binding affinity.  PPL-X1 is a ‘Platform Technology’ that represents a fundamentally new method of directly inhibiting the pathogenesis of hundreds of immune- complex diseases, for which there exists the need for more efficacious, non-toxic, lower cost therapeutics, or for which there are no treatment protocols.

Immune complex diseases occur when an antigen (a toxin, virus, bacteria, parasite, fungus or other foreign substance), induces an immune response in the body. These diseases are caused by the deposition of antigen-antibody or antigen-antibody-complement complexes on the surface of cells, resulting in the development of chronic or acute inflammation, which may manifest in the destruction of any tissue or organ in the body.

A non alternative allosteric inhibitor,   PPL-X1 has demonstrated absolute interruption of the disease inflammatory cytokine cascade, at its inception. By blocking the binding of antigens to Fc receptors, PPL-X1 would be able to perform as a ubiquitous therapeutic, in a manner that heretofore has never been achieved.